Skip to content

A study to assess the feasibility and safety of percutaneous transluminal coronary radio frequency treatment of the coronary artery fistula

A study to assess the feasibility and safety of percutaneous transluminal coronary radio frequency treatment of the coronary artery fistula - PTCRF

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066129
Enrollment
Unknown
Registered
2022-11-24
Start date
2022-11-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery fistula

Interventions

Sponsors

Guizhou Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients who were hospitalized in the Department of Cardiology of the people's Hospital of Guizhou Province from June 1, 2022 to December 31, 2025, and was diagnosed as coronary artery fistula (CAF) by coronary angiography, coronary CT or echocardiography, with a diameter of the fistula was >= 2 mm but = 1.3; 2. There are CAF-related symptoms such as chest tightness, chest pain and dyspnea, or CAF-related complications such as cardiac enlargement, pulmonary hypertension, and arrhythmia; 3. The patient's age ranged from 18 to 75 years; 4. There are no other diseases that may cause cardiac enlargement, pulmonary hypertension and arrhythmia; 5. There was no serious damage of liver and kidney function; 6. Life expectancy >= 1 year.

Exclusion criteria

Exclusion criteria: 1. Patients with CAF without symptoms or complications; 2. Fistula diameter 75 years; 4. Other diseases that may lead to cardiac enlargement, pulmonary hypertension or arrhythmia in the heart or outside the heart; 5. Severe damage of liver and kidney function; 6. Combined with malignant tumor or other serious diseases, life expectancy < 1 year; 7. Combined with diseases unsuitable for use of iodine-containing contrast agents; 8. Gestation.

Design outcomes

Primary

MeasureTime frame
Immediate success rate;Clinical success rate;

Countries

China

Contacts

Public ContactQiang Wu

Guizhou Provincial People's Hospital

gzgywq@126.com+86 139 8411 2269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026